Transparency Market Research (TMR) has published a new report titled, ‘Hospital acquired disease testing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027’. According to the report, the global hospital acquired disease testing market was valued at US$ 798.6 Mn in 2018 and is projected to expand at a CAGR of 14.7% from 2019 to 2027.
Read Report Overview - https://www.transparencymarketresearch.com/hospital-acquired-disease-testing.html
Overview
- Hospital acquired disease testing is used by health care professionals, especially by clinical laboratory technicians, for the diagnosis of nosocomial infection.
- The hospital acquired infection testing market has experienced strong growth in the last decade due to factors such as increased awareness about growth in the incidence of nosocomial infections globally and development of the innovative prevention and treatment solutions.
Increase in Prevalence of Hospital Acquired Infections to Drive Market
- Demand for hospital acquired infection testing has increased due to high prevalence of hospital acquired infection globally. Therefore, several hospitals are focusing on expanding their in-house test menu. Without an active and widespread surveillance, identification of cultures of colonized nosocomial microorganisms would yield poor results.
- Better surveillance cultures enable the detection of unrecognized pathogen colonized patients and also assist in prevention of transmission of infections. Countries in Europe such as the Netherlands, Finland, and Denmark with active surveillance systems for nosocomial infection detection have been successful in controlling hospital acquired infection caused by pathogens such as MRSA, thereby stabilizing resistance rates.
Request Brochure – https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1759
Urinary Tract Infection Segment to Dominate Market
- Based on test type, the global hospital acquired disease testing market has been divided into urinary tract, surgical site, pneumonia, bloodstream, MRSA, and others. Urinary tract infection is one of the most common infections with the highest prevalence globally, followed by surgical site infections. Other infections include respiratory, gastrointestinal, cardiovascular, bone, and joint-related infections.
- The global hospital acquired disease testing market is expanding at a promising rate owing to increasing prevalence of hospital-acquired infections, growing number of drug-resistant pathogens, and rising awareness among people regarding hospital-acquired diseases
- However, stringent regulations, guidance framework, and lack of budget and skilled labor in developing countries are expected to restrict the market growth during the forecast period
Request COVID Analysis on Hospital acquired disease testing Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=1759
North America to Dominate Global Market
- Geographically, the global hospital acquired infection testing market has been segmented into North America, Europe, Asia Pacific, and Middle East & Africa. North America led the largest market share in 2018. It was followed by Europe in the same year. The hospital acquired infection market in Europe is mature due to presence of strong and active nosocomial infection control and prevention authorities and guidelines such as the NHS in the U.K.
- Asia Pacific is a lucrative market for hospital acquired infection testing products as the overall prevalence of nosocomial infections in this region is high. Moreover, stringent guidelines have been set for the prevention and control of such conditions in the health care infrastructure in this region. Countries such as China, India, Japan, Thailand, Australia, and the Philippines are expected to be the major contributors to the hospital acquired infection testing market in Asia Pacific.
Request Customization on Hospital acquired disease testing Market Report –
https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=1759
Competitive Landscape
- The hospital acquired disease testing market is highly fragmented with a number of international and local players operating in the market. The companies profiled in the report include Abbott Laboratories, Alere, Inc., Becton, Dickinson and Company, bioMérieux SA, F. Hoffmann-La Roche Ltd., Hologic, Inc., Siemens Healthcare, Diatherix Laboratories, Inc., Meridian Bioscience, Inc., and Thermo Fisher Scientific, Inc.
The global hospital acquired disease testing market has been segmented as follows:
- Global Hospital acquired disease testing Market, by Test Type
- Urinary Tract Infection
- Surgical Site
- Pneumonia
- Bloodstream
- MRSA
- Others
- Global Hospital acquired disease testing Market, by Region
- North America
- S.
- Canada
- Europe
- Germany
- K.
- France
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia & New Zealand
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of Middle East & Africa
- North America
About Us
Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of analysts, researchers, and consultants, uses proprietary data sources and various tools and techniques to gather and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Contact
Transparency Market Research,
90 State Street, Suite 700,
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: [email protected]
Website: https://www.transparencymarketresearch.com/
According to the latest report by IMARC Group titled, “Hospital Acquired Disease Testing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024”, the market was worth US$ 876 Million in 2018.
Looking forward, IMARC expects the market to reach a value of US$ 2,190 Million by 2024, growing at a CAGR of around 16.5% during the next five years.Hospital-acquired disease (HAD) testing involves the diagnosis of infections and medical ailments potentially caused by bacterial, viral and fungal pathogens.
These ailments, including gastrointestinal, bloodstream and urinary tract infections (UTIs), are usually acquired from clinics, nursing homes, rehabilitation facilities or hospitals, when the outer layer of the skin comes in contact with pathogens which results in infections, especially after surgical operations.
HAD testing commonly involves molecular diagnostics, urinalysis, immunoassay and physical examination of the infected area.The global market is primarily driven by the increasing prevalence of HADs, especially in developing countries, owing to inadequate hygiene facilities available in the healthcare institutions.
Furthermore, technological advancements and innovations in testing equipment, which facilitate efficient diagnosis, monitoring and prevention of HADs, are also contributing to the increasing adoption of testing devices across the globe.
Other factors, including favorable government policies to improve healthcare infrastructure, along with an increasing number of research and development (R) activities in the healthcare sector, are projected to drive the market further.Request for a sample copy of this report: https://www.imarcgroup.com/hospital-acquired-disease-testing-market/requestsampleHospital Acquired Disease Testing Market Segmentation:Market Breakup by Indication1.
Value Market Research’s Global Hospital Acquired Disease Testing Market Report is a comprehensive analysis study that include industry trends, size, share, growth, estimation and forecast for the year 2020-2027.
The Hospital Acquired Disease Testing market report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.
The major players in the Hospital Acquired Disease Testing include Abbott Laboratories,Diatherix Laboratories, LLC,bioMérieux S.A.,Life Technologies Corporation,Cantel Medical Corp.,Meridian Bioscience, Inc.,QIAGEN GmbH,Nordion Inc.,Roche Holding AG,Becton, Dickinson and Company.
This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.Request FREE sample copy of the report “Global Hospital Acquired Disease Testing Market” at: https://www.valuemarketresearch.com/contact/hospital-acquired-disease-testing-market/download-sampleMarket SegmentationThe broad Hospital Acquired Disease Testing has been sub-grouped into the Test Type, End User and region.
The report studies these subsets with respect to the geographical segmentation.
The strategists can gain a detailed insight and devise appropriate strategies to target specific market.
